Developing new treatment methods for neurological diseases, with higher precision, greater efficacy and fewer side effects.

With one project nearing the clinical-study phase and one project in an early preclinical phase, CombiGene is the leading Nordic gene therapy company. Gene therapy has seen rapid development in recent years, with a number of approved therapies and several major corporate deals. During this period CombiGene built up a unique position with respect to knowledge within this field in the Nordic region. The company’s expertise covers all central areas of the gene therapy field: viral vectors, preclinical studies including biodistribution and toxicity studies, development of GMP-classed manufacturing methods, upscaling of production volumes and regulatory strategy.